Spots Global Cancer Trial Database for Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Official Title: An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma
Study ID: NCT00440388
Conditions
Study Description
Brief Summary: This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the rituximab regimen, improvement to patients' response to the treatment will be observed verses rituximab alone.
Detailed Description: Further Study Details provided by Ascenta.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Hematology Oncology Associates, Phoenix, Arizona, United States
Rocky Mountain Cancer Center-Aurora, Aurora, Colorado, United States
Florida Cancer Institute, Hudson, Florida, United States
Florida Cancer Institute, New Port Richey, Florida, United States
Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States
Central Indiana Cancer Centers, Fishers, Indiana, United States
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Hematology/Oncology Associates, Albuquerque, New Mexico, United States
New York Oncology Hematology, P.C., Albany, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Northwest Cancer Specialists, Portland, Oregon, United States
The Jones Clinic, Germantown, Tennessee, United States
Texas Oncology, P.A., Bedford, Texas, United States
Texas Cancer Center at Medical City, Dallas, Texas, United States
Texas Oncology, P.A., Fort Worth, Texas, United States
Allison Cancer Center, Midland, Texas, United States
HOAST - New Braunfels, New Braunfels, Texas, United States
West Texas Cancer Center, Odessa, Texas, United States
Hematology Oncology Physicians of Texas, Richardson, Texas, United States
Tyler Cancer Center, Tyler, Texas, United States
Virginia Oncology Associates, Chesapeake, Virginia, United States
Oncology and Hematology Associates of SW Virginia, Inc., Salem, Virginia, United States
Cancer Care Northwest, Spokane, Washington, United States
St. Mary's Medical Center, Huntington, West Virginia, United States
Contact Details
Name: Lance Leopold, MD
Affiliation: Ascenta Therapeutics, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
